Natera, Inc.
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Laboratory Partners & Hospitals Revenue by Quarter
Laboratory Partners & Hospitals Revenue — Institutional Payers ($M) ($M)
Natera Laboratory Partners & Hospitals Revenue: $37.7M in Q2 2026, up 70.2% from a year earlier.
Where the Q2 2026 figure comes from
Source: Form 10-Q (2026-08-07) ↗
Revenue from domestic and international laboratory distribution partners, hospital systems, and biopharma research partners.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Laboratory Partners & Hospitals Revenue — Institutional Payers ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 37.7 | +70.2% | Form 10-Q (2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 28.8 | +38.4% | Form 10-Q (2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 35.0 | +29.4% | Form 10-K (2026-02-27) ↗ |
| Q3 2025 | Sep 30, 2025 | 25.1 | -9.1% | Form 10-Q (2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 22.2 | -0.4% | Form 10-Q (2026-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 20.8 | +2.7% | Form 10-Q (2026-05-08) ↗ |
| Q4 2024 | Dec 31, 2024 | 27.1 | +0.6% | Form 10-K (2026-02-27) ↗ |
| Q3 2024 | Sep 30, 2024 | 27.6 | +27.1% | Form 10-Q (2025-11-07) ↗ |
| Q2 2024 | Jun 30, 2024 | 22.3 | -18.9% | Form 10-Q (2025-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 20.3 | -11.1% | Form 10-Q (2025-05-09) ↗ |
| Q4 2023 | Dec 31, 2023 | 26.9 | +7.7% | Form 10-K (2026-02-27) ↗ |
| Q3 2023 | Sep 30, 2023 | 21.7 | -19.7% | Form 10-Q (2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 27.5 | +24.0% | Form 10-Q (2024-08-09) ↗ |
| Q1 2023 | Mar 31, 2023 | 22.8 | +9.9% | Form 10-Q (2024-05-10) ↗ |
| Q4 2022 | Dec 31, 2022 | 25.0 | +11.3% | Form 10-K (2025-02-28) ↗ |
| Q3 2022 | Sep 30, 2022 | 27.1 | +55.1% | Form 10-Q (2023-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 22.1 | +41.9% | Form 10-Q (2023-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 20.7 | -53.4% | Form 10-Q (2023-05-10) ↗ |
| Q4 2021 | Dec 31, 2021 | 22.4 | +42.3% | Form 10-K (2024-02-29) ↗ |
| Q3 2021 | Sep 30, 2021 | 17.4 | +27.3% | Form 10-Q (2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | 15.6 | +19.6% | Form 10-Q (2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 44.5 | +184.0% | Form 10-Q (2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 15.8 | -11.4% | Form 10-K (2023-03-01) ↗ |
| Q3 2020 | Sep 30, 2020 | 13.7 | -19.1% | Form 10-Q (2021-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 13.0 | -13.8% | Form 10-Q (2021-08-06) ↗ |
| Q1 2020 | Mar 31, 2020 | 15.7 | +56.5% | Form 10-Q (2021-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 17.8 | +80.1% | Form 10-K (2022-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 16.9 | +84.9% | Form 10-Q (2020-11-06) ↗ |
| Q2 2019 | Jun 30, 2019 | 15.1 | +49.4% | Form 10-Q (2020-08-07) ↗ |
| Q1 2019 | Mar 31, 2019 | 10.0 | -32.7% | Form 10-Q (2020-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 9.88 | +4.7% | Form 10-K (2021-02-26) ↗ |
| Q3 2018 | Sep 30, 2018 | 9.16 | -1.4% | Form 10-Q (2019-11-08) ↗ |
| Q2 2018 | Jun 30, 2018 | 10.1 | +10.3% | Form 10-Q (2019-08-09) ↗ |
| Q1 2018 | Mar 31, 2018 | 14.9 | +84.1% | Form 10-Q (2019-05-10) ↗ |
| Q4 2017 | Dec 31, 2017 | 9.44 | – | Form 10-K (2020-03-02) ↗ |
| Q3 2017 | Sep 30, 2017 | 9.29 | – | Form 10-Q (2018-11-09) ↗ |
| Q2 2017 | Jun 30, 2017 | 9.18 | – | Form 10-Q (2018-08-09) ↗ |
| Q1 2017 | Mar 31, 2017 | 8.09 | – | Form 10-Q (2018-03-31) ↗ |
Cite this data
StockData. (2026). Natera Laboratory Partners & Hospitals Revenue ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/rev-payer-lab-partners
See every metric in the Natera KPI table. Data updated Nov 2, 2026.